Announced
Completed
Pfizer completed the acquisition of Metsera for $10bn.
Synopsis
Pfizer, a multinational pharmaceutical corporation, completed the acquisition of Metsera, a clinical-stage biopharmaceutical company, for $10bn. "This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it," Albert Bourla, Pfizer Chairman and CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Claim DealAll rights reserved. Copyright © 2025 Datasite